期刊文献+

他汀类药物对冠状动脉介入治疗后心肌无复流的预防

Prevention of statins on myocardial no-reflow after percutaneous coronary intervention
原文传递
导出
摘要 经皮冠状动脉介入治疗(PCI)后发生的无复流(NRF)严重影响患者的预后,而急性心肌梗死(AMI)患者PCI术后NRF的发生率可高达10%~30%。尽管NRF的防治方法众多,但临床疗效欠佳。已有的临床研究表明,长期接受他汀类药物治疗和术前7d短期的他汀类药物强化治疗,均可以降低AMI患者PCI术后NRF的发生,这为预防PCI术后心肌NRF开辟了一条新途径。 No-reflow(NRF)phenomenon after percutaneous coronary intervention(PCI)seriously affects the patient’s prognosis.The incidence of NRF in patients with acute myocardial infarction treated with PCI is up to 10%-30%.Despite the numerous methods of prevention and treatment of NRF,the clinical efficacy is poor.Existing clinical studies have shown that long-term statin therapy and preoperative seven days of short-term statin intensive treatment can reduce the occurrence of NRF.It will provide a new way for the prevention of NRF after PCI.
作者 张苏川
出处 《临床心血管病杂志》 CAS CSCD 北大核心 2012年第9期641-642,共2页 Journal of Clinical Cardiology
关键词 冠心病 他汀 无复流 介入治疗 coronary disease statins no-reflow percutaneous coronary intervention
  • 相关文献

参考文献3

二级参考文献11

  • 1FU Xiang-hua FAN Wei-ze GU Xin-shun WEI Yong-yun JIANG Yun-fa WU Wei-li LI Shi-qiang HAO Guo-zhen WEI Qing-min XUE Ling.Effect of intracoronary administration of anisodamine on slow reflow phenomenon following primary percutaneous coronary intervention in patients with acute myocardial infarction[J].Chinese Medical Journal,2007(14):1226-1231. 被引量:38
  • 2YUN K H, JEONG M H, KYU S, et al. The beneficial effect of high loading dose of rosuvastatin before percutaneous coronary intervention in patients with acute coronary syndrome[J]. Int J Cardiol,2009,137 : 246-251.
  • 3VESELKA J, ZEMANEK D, HAJEK P, et al Effect of two-day atorvastatin pretreatment on the Incidence of periprocedural myocardial infarction following elective percutaneous coronary intervention: a single-center, prospective, and randomized study[J]. Am J Cardiol,2009,104:630-633.
  • 4NICHOLLS S J, BRANDRUP-WOGNSEN G, PALMER M, et al. Meta-analysis of comparative efficacy of increasing dose of atorvastatin versus rosuvastatin versus Simvastatin on lowering levels of atherogenie lipids (from VOYAGER) [J]. Am J Cardiol,2010,105: 69-76.
  • 5RESNIC F S, WAINSTEIN M, LEE M K, et al. No-reflow is an independent predictor of death and myocardial infarction after percutaneous coronary intervention[J]. Am Heart J, 2003,145: 42- 46.
  • 6NICCOLI G, BURZOTTA F, GALIUTO L, et al. Myocardial no-reflow in humans[J]. J Am Coll Cardiol,2009,54 : 281- 292.
  • 7ROSS A M, GIBBONS R J, STONE G W, et al. AMISTAD-Ⅱ Investigators. A randomized, double blinded, placebo-controlled muhicenter trial of adenosine as an adjunct to reperfusion in the treatment of acute myocardial infarction (AMISTAD-Ⅱ)[J]. J Am Coll Cardiol, 2005,45 : 1775 - 1780.
  • 8STONE G W, WEBB J, COX D A, et al. Enhanced myocardial efficacy and recovery by aspiration of liberated debris (EMERALD) investigators. Distal microcirculatory protection during percutaneous coronary intervention in acute ST-segment elevation myocardial infarction: a randomized controlled trial[J]. JAMA, 2005,293 : 1063- 1072.
  • 9DING Chao,FU Xiang-hua,HE Zhen-shan,CHEN Hui-xiao,XUE Ling,LI Jun-xia.Cardioprotective effects of simvastatin on reversing electrical remodeling induced by myocardial ischemia-reperfusion in normocholesterolemic rabbits[J].Chinese Medical Journal,2008(6):551-556. 被引量:26
  • 10张红雨,王佩显,曹艳君,吴志国,刘汉书.冠状动脉内注射替罗非班对急性心肌梗死患者介入治疗中无复流现象的疗效研究[J].临床心血管病杂志,2011,27(1):25-29. 被引量:49

共引文献35

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部